A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer Article

Full Text via DOI: 10.1080/15384047.2015.1026481 PMID: 25928118 Web of Science: 000354981300006

Cited authors

  • Cowherd, S.; Miller, L. D.; Melin, S. A.; Akman, S.; Isom, S.; Cole, J.; Pullikuth, A.; Lawrence, J. A.


  • Purpose: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. Methods: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6mg/kg on days 1 and 15 for a cycle length of 28days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. Results: Fourteen patients with TNBC were enrolled with a median age of 53years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. Conclusions: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC.


Publication date

  • 2015

Published in


International Standard Serial Number (ISSN)

  • 1538-4047

Start page

  • 678

End page

  • 683


  • 16


  • 5